MICHAEL J O'CONNELL

Summary

Affiliation: National Surgical Adjuvant Breast and Bowel Project
Country: USA

Publications

  1. pmc Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin
    MICHAEL J O'CONNELL
    National Surgical Adjuvant Breast and Bowel Project, University of Pittsburgh, Pittsburgh, PA 15212, USA
    J Clin Oncol 28:3937-44. 2010
  2. doi request reprint Survival following recurrence in stage II and III colon cancer: findings from the ACCENT data set
    MICHAEL J O'CONNELL
    National Surgical Adjuvant Breast and Bowel Project Operations Office, Pittsburgh, PA 15212 5234, USA
    J Clin Oncol 26:2336-41. 2008
  3. pmc Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses
    Greg Yothers
    NSABP Biostatistical Center, One Sterling Plaza, 201 N Craig St, STE 350, Pittsburgh, PA 15213, USA
    J Clin Oncol 29:3768-74. 2011
  4. pmc Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials
    Greg Yothers
    National Surgical Adjuvant Breast and Bowel Project Biostatistical Center, One Sterling Plaza, 201 N Craig St, Pittsburgh, PA 15213, USA
    J Natl Cancer Inst 103:1498-506. 2011
  5. ncbi request reprint Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06
    Barry C Lembersky
    National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA 15212, USA
    J Clin Oncol 24:2059-64. 2006
  6. pmc Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03
    Mark S Roh
    National Surgical Adjuvant Breast and Bowel Project NSABP Operations Cente, University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA, USA
    J Clin Oncol 27:5124-30. 2009
  7. pmc Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer
    Carmen J Allegra
    Department of Biostatistics, University of Pittsburgh, PA, USA
    J Clin Oncol 27:3385-90. 2009
  8. pmc FOLFOX and FLOX regimens for the adjuvant treatment of resected stage II and III colon cancer
    Saima Sharif
    National Surgical Adjuvant Breast and Bowel Project Operations Office, Pittsburgh, Pennsylvania, USA
    Cancer Invest 26:956-63. 2008
  9. pmc Defective mismatch repair and benefit from bevacizumab for colon cancer: findings from NSABP C-08
    Kay Pogue-Geile
    National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA 15212, USA
    J Natl Cancer Inst 105:989-92. 2013
  10. pmc Primary mFOLFOX6 plus bevacizumab without resection of the primary tumor for patients presenting with surgically unresectable metastatic colon cancer and an intact asymptomatic colon cancer: definitive analysis of NSABP trial C-10
    Laurence E McCahill
    National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA, USA
    J Clin Oncol 30:3223-8. 2012

Detail Information

Publications16

  1. pmc Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin
    MICHAEL J O'CONNELL
    National Surgical Adjuvant Breast and Bowel Project, University of Pittsburgh, Pittsburgh, PA 15212, USA
    J Clin Oncol 28:3937-44. 2010
    ....
  2. doi request reprint Survival following recurrence in stage II and III colon cancer: findings from the ACCENT data set
    MICHAEL J O'CONNELL
    National Surgical Adjuvant Breast and Bowel Project Operations Office, Pittsburgh, PA 15212 5234, USA
    J Clin Oncol 26:2336-41. 2008
    ....
  3. pmc Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses
    Greg Yothers
    NSABP Biostatistical Center, One Sterling Plaza, 201 N Craig St, STE 350, Pittsburgh, PA 15213, USA
    J Clin Oncol 29:3768-74. 2011
    ..This analysis is the first publication of overall survival (OS) for the NSABP C-07 study. We updated DFS and examined both end points in clinically relevant patient subsets...
  4. pmc Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials
    Greg Yothers
    National Surgical Adjuvant Breast and Bowel Project Biostatistical Center, One Sterling Plaza, 201 N Craig St, Pittsburgh, PA 15213, USA
    J Natl Cancer Inst 103:1498-506. 2011
    ..We investigated whether disparities in survival and related endpoints would persist when patients were treated with identical therapies in controlled clinical trials...
  5. ncbi request reprint Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06
    Barry C Lembersky
    National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA 15212, USA
    J Clin Oncol 24:2059-64. 2006
    ....
  6. pmc Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03
    Mark S Roh
    National Surgical Adjuvant Breast and Bowel Project NSABP Operations Cente, University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA, USA
    J Clin Oncol 27:5124-30. 2009
    ..The NSABP R-03 (National Surgical Adjuvant Breast and Bowel Project R-03) trial compared neoadjuvant versus adjuvant chemoradiotherapy in the treatment of locally advanced rectal carcinoma...
  7. pmc Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer
    Carmen J Allegra
    Department of Biostatistics, University of Pittsburgh, PA, USA
    J Clin Oncol 27:3385-90. 2009
    ..We present safety information in advance of the planned analysis of efficacy...
  8. pmc FOLFOX and FLOX regimens for the adjuvant treatment of resected stage II and III colon cancer
    Saima Sharif
    National Surgical Adjuvant Breast and Bowel Project Operations Office, Pittsburgh, Pennsylvania, USA
    Cancer Invest 26:956-63. 2008
    ..The benefit of oxaliplatin appears to be independent of the 5-FU/LV regimen used. This paper reviews the efficacy and toxicities of these two regimens and is meant to serve as a guide for clinical practice...
  9. pmc Defective mismatch repair and benefit from bevacizumab for colon cancer: findings from NSABP C-08
    Kay Pogue-Geile
    National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA 15212, USA
    J Natl Cancer Inst 105:989-92. 2013
    ....
  10. pmc Primary mFOLFOX6 plus bevacizumab without resection of the primary tumor for patients presenting with surgically unresectable metastatic colon cancer and an intact asymptomatic colon cancer: definitive analysis of NSABP trial C-10
    Laurence E McCahill
    National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA, USA
    J Clin Oncol 30:3223-8. 2012
    ..Surgical resection of asymptomatic IPT is controversial...
  11. ncbi request reprint Randomized clinical trial of high-dose levamisole combined with 5-fluorouracil and leucovorin as surgical adjuvant therapy for high-risk colon cancer
    MICHAEL J O'CONNELL
    Department of Medical Oncology, Allegheny General Hospital, Pittsburgh, PA, USA
    Clin Colorectal Cancer 6:133-9. 2006
    ..A clinical trial was designed to test the value of levamisole given at its maximum tolerated dose in combination with 5-FU-based chemotherapy...
  12. pmc Conditional survival and the choice of conditioning set for patients with colon cancer: an analysis of NSABP trials C-03 through C-07
    Beth A Zamboni
    Department of Biostatistics, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA
    J Clin Oncol 28:2544-8. 2010
    ..We extend the concept of CS to condition on the set of patients alive, recurrence-free, and second primary cancer-free (disease-free survival [OS|DFS])...
  13. ncbi request reprint Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07
    Stephanie R Land
    National Surgical Adjuvant Breast and Bowel Project Operations Office and Biostatistical Center, Pittsburgh, PA 15213, USA
    J Clin Oncol 25:2205-11. 2007
    ..Definitive analysis revealed an increase in 4-year disease-free survival from 67.0% to 73.2% in favor of FLOX. This study compares neurotoxicity between the treatments...
  14. ncbi request reprint Surgical adjuvant therapy for colorectal cancer: current approaches and future directions
    Dulabh K Monga
    Department of Human Oncology, Allegheny Cancer Center, Allegheny General Hospital, 320 East North Avenue, 5th Floor, Pittsburgh, Pennsylvania 15212, USA
    Ann Surg Oncol 13:1021-34. 2006
    ..Clinical trials are under way to address this issue. Thus, it will be advantageous to be able to tailor therapy individually, according to the risk of recurrence...
  15. doi request reprint Mutation profiling and microsatellite instability in stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive value
    Patrick G Gavin
    National Surgical Adjuvant Breast and Bowel Project, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA 15212, USA
    Clin Cancer Res 18:6531-41. 2012
    ..The purpose of this study was to examine the prognostic and oxaliplatin predictive value of mismatch repair (MMR) status and common hot spot mutations, which we previously identified in stage II and III colon cancer...
  16. pmc The half century of clinical trials of the National Surgical Adjuvant Breast And Bowel Project
    D Lawrence Wickerham
    NSABP Operations Office, Biostatistical Center and Graduate School of Public Health, University of Pittsburgh, and Department of Human Oncology, Allegheny General Hospital, Pittsburgh, PA 15212, USA
    Semin Oncol 35:522-9. 2008
    ....